|
|
|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Stakeholder Opinions: Asthma Phenotypes A changing paradigm
An estimated 34 million people are diagnosed with asthma in the major markets. The disease can be broken down into various phenotypes, differentiated by severity, trigger, or predominant inflammatory type. These phenotypes may have important consequen
Stakeholder Insight: Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a chronic inflammatory condition that affects the gastrointestinal tract causing a number of distressing symptoms such as bleeding, diarrhea and abdominal pain. IBD includes key subsets Crohn’s disease and ulc
Stakeholder Opinions: Sepsis
Key issues surrounding product development for sepsis, severe sepsis and septic shock. Analysis of the major clinical and commercial defining the four key areas of optimised individual treatment: predisposition, infection, response and organ failure.<
Autoimmune Market Outlook to 2012
A new report examining how the competitive dynamics of major pharma companies will influence the market positions of products and shape the direction of future global autoimmunology.
Commercial Insight: Asthma & COPD - Combination products...
Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major mark
Commercial Insight: Autoimmune Overview
The autoimmune disease market will be rapidly growing due to a high number of competitive brands currently on the market and a full pipeline. Company strategies include expanding the treatment algorithm by pursuing approval for ’early’ dis
Juvenile Arthritis - A Niche In The Market
Juvenile arthritis is the next indication due for approval for blockbuster biologic therapies Remicade (infliximab) and Humira (adalimumab). Pediatric rheumatology is a growing specialty that offers high unmet need in terms of effective well-tested tr
Stakeholder Insight: COPD - Another Reason to Quit
COPD is a deadly disease of the elderly, with patients suffering years of progressive discomfort and disability with no pharmacological interventions able to slow the progressive decline in lung function. A large, increasing patient population demands
Commercial Insight: Asthma and COPD - Get SMART
There is a positive outlook for the respiratory market over the next five years, which will experience a sustained period of growth driven by the expansion of sales in existing classes, the launch of major new products, and the results from several la
Stakeholder Insight: Asthma - Combination Therapy
According to the US National Heart, Lung, and Blood Institute and the European Respiratory Society, the annual cost of asthma is estimated to be $16.1 billion in the US and $16.3 billion in the EU. Over 41.5 million people, equivalent to the population
|
